A recent study has suggested that weight loss injections should be explored as potential agents for preventing cancer, particularly cancers associated with obesity. Obesity is known to increase the risk of various types of cancer, such as breast, bowel, pancreas, kidney, liver, and stomach cancers.
The study focused on Glucagon-like peptide-1 receptor agonist (GLP-1) drugs like Mounjaro, Wegovy, and Ozempic, which are commonly used to manage obesity and type 2 diabetes. Research indicates that these drugs may offer broader health benefits beyond their primary purposes.
Examining data from over 161,000 obese patients without diabetes or a history of obesity-related cancer, researchers found that those who received weight-loss injections were significantly less likely to develop obesity-related cancers during the two-year follow-up period, with a 41% reduced risk.
Lead author of the study, Dr. Aparna Kamat, noted that the reduction in cancer risk was more pronounced in certain groups, such as men who saw a nearly 70% drop in risk. Among gynaecologic cancers, there was a 58% decrease in endometrial cancer incidence, a cancer closely associated with obesity.
The study also highlighted disparities in risk reduction among different racial groups, with white patients experiencing a 50% reduction while the same effect was not observed in black patients. Dr. Kamat emphasized that while the findings do not establish causation, they suggest a potential for GLP-1 medications to play a role in cancer prevention.
According to Professor Pedro Ramirez, co-author of the study, the results hint at additional benefits of GLP-1 drugs beyond weight management, warranting further investigation through long-term clinical trials. The study underscores the evolving landscape of obesity treatment and cancer prevention, signaling the importance of exploring the broader health impacts of GLP-1 medications as obesity-related cancers become more prevalent among middle-aged adults.